Predicting weight loss and maintenance in overweight/obese pediatric patients

Susanna Wiegand1, Klaus-Michael Keller, Thomas Lob-Corzilius

  • 1Department of Pediatric Endocrinology and Diabetology, Charité University Medicine, Berlin, Germany.

Insights

Long-term weight patterns in overweight children show varied outcomes. Interventions before puberty appear most effective for sustained weight management in pediatric obesity.

Area of Science:

  • Pediatric Endocrinology
  • Obesity Research
  • Public Health

Background:

  • Pediatric lifestyle interventions show short-term success in obese patients.
  • Long-term effects of these interventions are understudied in Europe.
  • This study examines long-term weight changes in a Central European pediatric cohort.

Purpose of the Study:

  • To investigate long-term weight trajectories in overweight children.
  • To identify sociodemographic predictors of weight change in pediatric obesity.
  • To evaluate the effectiveness of interventions over time.

Main Methods:

  • Retrospective analysis of the APV database (Adiposity Patients Verlaufsbeobachtung).
  • Included 29,181 patients (5-25 years old) with BMI ≥ 90th percentile from 157 centers.
  • Analyzed BMI standard deviation scores (BMI-SDS) over a 2-year follow-up using logistic regression.

Main Results:

  • Five distinct weight trajectories were identified: 'rapid weight loss', 'delayed success', 'cycling weight', 'initial weight loss and weight rebound', and 'no weight loss throughout'.
  • 40.7% of patients showed no weight loss, while 23.4% achieved rapid weight loss.
  • Younger age and male sex were associated with better weight reduction and maintenance.

Conclusions:

  • Intervention before puberty is promising for long-term weight maintenance in overweight children.
  • New strategies are needed to enhance long-term treatment success for children with poorer outcomes.
  • Early intervention is key for sustained pediatric obesity management.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
351
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
392
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
935
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
895